Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KD-347N
- Development stage
- Preclinical
- Lead developer
- Nanjing KAEDI Biotherapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KD-347N is an investigational chimeric antigen receptor (CAR) modified Natural Killer (NK)/T cell therapy currently in preclinical development by KAEDI Medical. This therapeutic candidate utilizes a CAR-NK/T cell platform, which typically involves engineering immune cells that possess characteristics of both Natural Killer cells and T cells (such as NKT cells) to express a chimeric antigen receptor. This approach aims to combine the rapid, MHC-independent cytotoxicity of NK cells with the robust expansion and memory functions of T cells. While the specific molecular target and primary disease indications for KD-347N are currently undisclosed by the developer, the program is part of a broader effort to develop next-generation cell therapies for oncological applications.
- Other names
- KD-347N-KAEDI Medical-CAR-NK/T cell therapy
Beyond the preview
Go deeper on KD-347N.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KD-347N.